Mao Kaili, Camparo Philippe, Badoual Cecile, Peyromaure Michaël, Delongchamps Nicolas Barry, Vieillefond Annick, Dinh-Xuan Anh-Tuan
Department of Urology, Cochin hospital, 75014 Paris, France.
Oncol Rep. 2008 Jan;19(1):171-5.
In the current study, we analysed the prognostic value of vascular endothelial growth factor receptor-1 (VEGFR-1) in clinically-localized prostate cancer (PCa). Forty patients who had undergone radical prostatectomy (RP) for clinically-localized PCa were included. Two groups were compared: 17 patients who experienced cancer progression following RP (group 1) and 23 patients who remained free of recurrence after intervention (group 2). Paraffin-embedded sections obtained from the RP specimens of the 40 patients were used to build tissue microarrays. The expression of VEGFR-1 was examined in the RP specimens using immunohistochemistry and was compared between the groups of patients. The two groups had similar tumor characteristics in terms of PSA, Gleason score and pathological stage of cancer. The median intensity score of VEGFR-1 expression was significantly higher in pT3 tumors than in pT2 tumors. Nevertheless, the intensity scores of VEGFR-1 expression were similar in the two groups of patients. Our results suggest that VEGFR-1 expression is not associated with the risk of cancer progression following RP. Therefore, VEGFR-1 may not be of prognostic value in clinically-localized PCa.
在本研究中，我们分析了血管内皮生长因子受体-1（VEGFR-1）在临床局限性前列腺癌（PCa）中的预后价值。纳入了40例因临床局限性PCa接受根治性前列腺切除术（RP）的患者。比较了两组：17例RP后出现癌症进展的患者（第1组）和23例干预后无复发的患者（第2组）。从40例患者的RP标本中获取石蜡包埋切片，用于构建组织微阵列。使用免疫组织化学检测RP标本中VEGFR-1的表达，并在患者组之间进行比较。两组在前列腺特异性抗原（PSA）、 Gleason评分和癌症病理分期方面具有相似的肿瘤特征。VEGFR-1表达的中位强度评分在pT3肿瘤中显著高于pT2肿瘤。然而，两组患者中VEGFR-1表达的强度评分相似。我们的结果表明，VEGFR-1表达与RP后癌症进展风险无关。因此，VEGFR-1在临床局限性PCa中可能没有预后价值。
